title: Pregnancy-associated venous thromboembolism (VTE) in combined heterozygous factor V Leiden (FVL) and prothrombin (FII) 20210 A mutation and in heterozygous FII single gene mutation alone.
abstract: The risk of venous thromboembolism (VTE) in the absence of prophylaxis was evaluated in a retrospective study of 47 women (84 pregnancies) with combined thrombophilia [heterozygous factor V Leiden (FVL) plus prothrombin (FII) 20210A mutation (group I)] and in 82 women (193 pregnancies) with the FII alone (group II). VTE was more frequent in group I than in group II [17.8% versus 6.2%, P = 0.003, relative risk (RR) 2.9, 95% confidence interval (CI) 1.4-5.9], ante partum (7.1% and 2.1%) and post partum (11.5% and 4.2%). The risk was higher in index cases than in family members (RR 2.5, 95% CI 1.2-5.2 and RR 2.1, 95% CI 0.2-22.3 respectively) Even women who had no history of VTE before pregnancy had an increased risk (RR 2.2, 95% CI 1.0-4.8). Our results suggest that, during ante partum, prophylaxis is indicated in women with combined thrombophilia and with a VTE before pregnancy. In those without VTE before pregnancy, prophylaxis might be decided for each individual case, taking into consideration all risk factors. In women with the FII mutation alone, the low risk may not justify prophylaxis in the absence of previous VTE. In post partum, prophylaxis is indicated in all cases.
authors.affiliation: Hemostasis and Thrombosis Unit, Hotel-Dieu Hospital, Paris, France. labo.hematologie@htd.ap-hop-paris.fr
authors.forename: Meyer-Michel
authors.initials: MM
authors.lastname: Samama
authors.forename: Roberto A
authors.initials: RA
authors.lastname: Rached
authors.forename: Marie-Hélène
authors.initials: MH
authors.lastname: Horellou
authors.forename: Sandro
authors.initials: S
authors.lastname: Aquilanti
authors.forename: Valérie G
authors.initials: VG
authors.lastname: Mathieux
authors.forename: Geneviève
authors.initials: G
authors.lastname: Plu-Bureau
authors.forename: Ismail
authors.initials: I
authors.lastname: Elalamy
authors.forename: Jacqueline
authors.initials: J
authors.lastname: Conard
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000925:Anticoagulants / Q000627:therapeutic use; D005165:Factor V / Q000235:genetics*; D005260:Female; D006493:Heparin / Q000627:therapeutic use; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D009154:Mutation; D011247:Pregnancy; D011249:Pregnancy Complications, Cardiovascular / Q000517:prevention & control; D011295:Prenatal Care / Q000379:methods; D011516:Prothrombin / Q000235:genetics*; D012189:Retrospective Studies; D018570:Risk Assessment; D013923:Thromboembolism / Q000235:genetics / Q000517:prevention & control; D020246:Venous Thrombosis / Q000235:genetics* / Q000517:prevention & control
chemical_list: D000925:Anticoagulants; C095381:factor V Leiden; D005165:Factor V; D011516:Prothrombin; D006493:Heparin